1. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- Author
-
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, and Ivan G. Gordeev
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,favipiravir ,Favipiravir ,Marketing authorization ,Antiviral Agents ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Interim ,medicine ,Humans ,030212 general & internal medicine ,Stage (cooking) ,SARS-CoV-2 ,business.industry ,Brief Report ,COVID-19 ,Clinical trial ,AcademicSubjects/MED00290 ,Treatment Outcome ,Infectious Diseases ,RNA Polymerase Inhibitor ,AVIFAVIR ,Drug Therapy, Combination ,business - Abstract
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
- Published
- 2020
- Full Text
- View/download PDF